DK0618968T3 - Midler til diagnostisering og behandling af Alzheimer's sygdom - Google Patents
Midler til diagnostisering og behandling af Alzheimer's sygdomInfo
- Publication number
- DK0618968T3 DK0618968T3 DK93901671T DK93901671T DK0618968T3 DK 0618968 T3 DK0618968 T3 DK 0618968T3 DK 93901671 T DK93901671 T DK 93901671T DK 93901671 T DK93901671 T DK 93901671T DK 0618968 T3 DK0618968 T3 DK 0618968T3
- Authority
- DK
- Denmark
- Prior art keywords
- epitopes
- tau protein
- alzheimer
- disease
- diagnosing
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 102000013498 tau Proteins Human genes 0.000 abstract 4
- 108010026424 tau Proteins Proteins 0.000 abstract 4
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91120974A EP0544942A1 (en) | 1991-12-06 | 1991-12-06 | Novel tools for the diagnosis and treatment of Alzheimer disease |
EP92119551 | 1992-11-16 | ||
PCT/EP1992/002829 WO1993011231A1 (en) | 1991-12-06 | 1992-12-07 | Tools for the diagnosis and treatment of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0618968T3 true DK0618968T3 (da) | 2000-04-10 |
Family
ID=26129111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93901671T DK0618968T3 (da) | 1991-12-06 | 1992-12-07 | Midler til diagnostisering og behandling af Alzheimer's sygdom |
Country Status (10)
Country | Link |
---|---|
US (2) | US6200768B1 (da) |
EP (5) | EP0911398B1 (da) |
JP (4) | JPH07507044A (da) |
AT (4) | ATE386115T1 (da) |
AU (2) | AU681071B2 (da) |
CA (1) | CA2125298A1 (da) |
DE (4) | DE69233736D1 (da) |
DK (1) | DK0618968T3 (da) |
ES (2) | ES2136654T3 (da) |
WO (1) | WO1993011231A1 (da) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6010913A (en) * | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
JPH06239899A (ja) * | 1993-02-12 | 1994-08-30 | Teijin Ltd | ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法 |
GB2295395B (en) * | 1993-08-12 | 1998-04-01 | Inst Of Psychiatry | Models of Alzheimer's disease |
GB9316727D0 (en) * | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
PT737208E (pt) * | 1993-12-21 | 2006-12-29 | Innogenetics Nv | Anticorpos monoclonais específicos para phf-tau, hibridomas que os segregam, reconhecimento de antigénios por estes anticorpos e suas aplicações |
CA2195672A1 (en) * | 1994-07-29 | 1996-02-15 | Eugeen Vanmechelen | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
GB9610829D0 (en) | 1996-05-23 | 1996-07-31 | Medical Res Council | Screening of agents for treatment of azlheimers disease |
US7252950B1 (en) | 1997-09-04 | 2007-08-07 | The Regents Of The University Of California | Assays for detecting modulators of cytoskeletal function |
WO1999011814A1 (en) * | 1997-09-04 | 1999-03-11 | Board Of Trustees Of Leland Stanford Jr. University | Assays for detecting modulators of cytoskeletal function |
US6797478B1 (en) | 1998-03-05 | 2004-09-28 | University Of Cincinnati | Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies |
AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
US20020002270A1 (en) * | 1999-06-16 | 2002-01-03 | Raymond P. Zinkowski | Purified antigen for alzheimer's disease, and methods of obtaining and using same |
US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
US7146209B2 (en) * | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
EP1925315A3 (en) * | 2001-02-27 | 2009-11-18 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
DE08002964T1 (de) | 2001-02-27 | 2009-09-03 | Blanchette Rockefeller Neurosciences Institute | Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung |
GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
EA007576B1 (ru) | 2001-09-21 | 2006-12-29 | Мицубиси Фарма Корпорейшн | Производные 3-замещенных 4-пиримидонов |
PL368816A1 (en) | 2001-09-21 | 2005-04-04 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
US7794965B2 (en) * | 2002-03-13 | 2010-09-14 | Signum Biosciences, Inc. | Method of identifying modulators of PP2A methylase |
US20050266099A1 (en) * | 2002-04-25 | 2005-12-01 | Alon Shalev | Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
US7684859B2 (en) * | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
JP2006515999A (ja) * | 2002-11-14 | 2006-06-15 | ブレインズゲート リミティド | 刺激のための外科用ツール及び技法 |
ZA200505258B (en) | 2002-12-16 | 2006-09-27 | Mitsubishi Pharma Corp | 3-Substituted-4-pyrimidone derivatives |
CA2511665A1 (en) * | 2002-12-18 | 2004-07-01 | Novartis Ag | Endothelial cell specifically binding peptides |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
GB2398533B (en) * | 2003-02-19 | 2005-11-16 | Gillette Co | Safety razors |
TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
WO2005058374A1 (en) * | 2003-12-15 | 2005-06-30 | Tongji Medical Center | Methods and compositions for modulating tau in vivo |
US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
WO2006021957A2 (en) * | 2004-08-23 | 2006-03-02 | Brainsgate Ltd. | Concurrent bilateral spg modulation |
CN101084204B (zh) | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
EP1843734A4 (en) * | 2005-02-03 | 2008-09-10 | Signum Biosciences Inc | COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
US20070134724A1 (en) * | 2005-08-04 | 2007-06-14 | Peter Davies | Phosphorylation of tau by abl |
US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
SG2014013437A (en) | 2005-11-30 | 2014-07-30 | Abbott Lab | Monoclonal antibodies and uses thereof |
PT2004155T (pt) | 2006-03-29 | 2018-05-02 | Wista Lab Ltd | Inibidores de agregação proteica |
EP2013191B3 (en) | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US20090210026A1 (en) * | 2006-08-17 | 2009-08-20 | Brainsgate Ltd. | Spg stimulation for enhancing neurogenesis and brain metabolism |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008089961A1 (en) * | 2007-01-22 | 2008-07-31 | University Of Zurich | Use of phosphatase inhibitors for the treatment of neurodegenerative diseases |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
WO2010014585A1 (en) | 2008-07-28 | 2010-02-04 | Blanchette Rockefeller Neurosciences Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
EP2669386A1 (en) | 2008-07-28 | 2013-12-04 | Blanchette Rockefeller Neurosciences Institute | Stimulus-elicited genomic profile markers of alzheimer's disease |
US9464122B2 (en) * | 2008-08-20 | 2016-10-11 | Oligomerix, Inc. | Methods and compositions comprising tau oligomers |
US20110312059A1 (en) * | 2008-08-20 | 2011-12-22 | Oligomerix Inc. | Tau protease compositions and methods |
FR2940972B1 (fr) * | 2009-01-09 | 2015-07-31 | Isp Investments Inc | Nouveaux peptides anti-age et composition cosmetique et/ou pharmaceutique les contenant |
EP2440234A4 (en) * | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
WO2011013034A1 (en) * | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
US9125846B2 (en) | 2010-10-15 | 2015-09-08 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
JP6124591B2 (ja) * | 2009-08-28 | 2017-05-10 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | タウオリゴマーに結合する抗体 |
US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
CN102549438B (zh) | 2009-09-24 | 2014-10-29 | 国家健康与医学研究院 | Fkbp52-tau相互作用作为新颖治疗靶点用于治疗涉及tau机能失调的神经障碍 |
US20110144029A1 (en) * | 2009-09-30 | 2011-06-16 | Board Of Regents, The University Of Texas System | Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases |
EP2483684B1 (en) | 2009-10-02 | 2018-04-18 | Blanchette Rockefeller Neurosciences, Institute | Fibroblast growth patterns to diagnose alzheimer's disease |
MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
JP6147665B2 (ja) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | アミロイドベータ結合タンパク質 |
MX338421B (es) | 2010-10-07 | 2016-04-15 | Ac Immune Sa | Anticuerpos fosfoespecificos que reconocen la proteina tau. |
US9283230B2 (en) | 2011-02-11 | 2016-03-15 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
WO2012146285A1 (en) | 2011-04-28 | 2012-11-01 | Universität Leipzig | Polymutant tau protein variants and their use for recapitulating human tauopathies |
US9506051B2 (en) | 2011-05-20 | 2016-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
UA115657C2 (uk) | 2011-09-19 | 2017-12-11 | Аксон Ньюросайєнс Сє | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла |
RU2639537C2 (ru) * | 2011-10-07 | 2017-12-21 | Ац Иммуне С.А. | Фосфоспецифичные антитела, распознающие тау |
EP2780316B1 (en) | 2011-11-13 | 2020-04-15 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla and methods of treatment using the same |
JP6345655B2 (ja) | 2012-07-03 | 2018-06-20 | ワシントン・ユニバーシティWashington University | タウに対する抗体 |
WO2014141124A1 (en) * | 2013-03-13 | 2014-09-18 | Institut National De La Sante Et De La Recherche Medicale | Erk-pathway activating compound for preventing or treating leptin resistance |
RU2661111C2 (ru) | 2013-03-15 | 2018-07-11 | Ац Иммуне С.А. | Антитела к тау и способы применения |
EP2878335B1 (en) | 2013-11-10 | 2018-01-03 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
WO2015091656A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
US10132818B2 (en) | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
WO2016112078A2 (en) * | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
EP3093043B1 (en) | 2015-05-13 | 2018-11-14 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
CN107810196B (zh) | 2015-06-24 | 2021-11-05 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
EP3334453A4 (en) | 2015-08-13 | 2019-02-06 | New York University | SPECIFIC ANTIBODY MOLECULES OF THE ASP421 EPITOPE TRUNCATED FROM THE TAU PROTEIN AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY |
KR102603963B1 (ko) | 2015-11-24 | 2023-11-20 | 메사추세츠 인스티튜트 오브 테크놀로지 | 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법 |
JOP20200228A1 (ar) | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
LT3484916T (lt) | 2016-07-12 | 2021-04-26 | H. Lundbeck A/S | Antikūnai, būdingi hiperfosforilintam tau, ir jų naudojimo būdai |
EP3565836A1 (en) | 2017-01-04 | 2019-11-13 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases |
US10960225B2 (en) | 2017-10-10 | 2021-03-30 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function |
JP2020536653A (ja) | 2017-10-10 | 2020-12-17 | マサチューセッツ インスティテュート オブ テクノロジー | 認知症の予防、緩和および/または治療のためのシステムならびに方法 |
KR20200086277A (ko) * | 2017-10-10 | 2020-07-16 | 메사추세츠 인스티튜트 오브 테크놀로지 | 뇌에서 감마 진동을 동기화하기 위해 시각 자극을 이용한 치매 치료 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4874694A (en) * | 1987-04-07 | 1989-10-17 | The Rockefeller University | Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders |
DE3726721A1 (de) * | 1987-08-11 | 1989-02-23 | Koehler Chemie Dr Franz | Verwendung eines calcium-chelats der ethanolaminophosphorsaeure zur prophylaxe oder therapie |
GB8724412D0 (en) * | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
JPH0725786A (ja) * | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
IE911869A1 (en) * | 1990-06-01 | 1991-12-04 | Regeneron Pharma | A family of map2 protein kinases |
DE4028970A1 (de) | 1990-09-12 | 1992-03-19 | Kettner Verpackungsmaschf | Transportrolle |
DE69232121T2 (de) * | 1991-08-09 | 2002-06-20 | Massachusetts Inst Technology | Verwendungen einer proteinkinase von ton und neurofilament pk40 |
US6579691B1 (en) * | 1994-10-28 | 2003-06-17 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften, E.V. | Protein kinase NPK-110 |
-
1992
- 1992-12-07 ES ES93901671T patent/ES2136654T3/es not_active Expired - Lifetime
- 1992-12-07 CA CA002125298A patent/CA2125298A1/en not_active Abandoned
- 1992-12-07 EP EP98121175A patent/EP0911398B1/en not_active Expired - Lifetime
- 1992-12-07 EP EP98121177A patent/EP0909814B1/en not_active Expired - Lifetime
- 1992-12-07 AT AT98121177T patent/ATE386115T1/de not_active IP Right Cessation
- 1992-12-07 DE DE69233736T patent/DE69233736D1/de not_active Expired - Lifetime
- 1992-12-07 JP JP5509840A patent/JPH07507044A/ja active Pending
- 1992-12-07 AT AT98121176T patent/ATE438716T1/de not_active IP Right Cessation
- 1992-12-07 AT AT93901671T patent/ATE185599T1/de not_active IP Right Cessation
- 1992-12-07 WO PCT/EP1992/002829 patent/WO1993011231A1/en not_active Application Discontinuation
- 1992-12-07 EP EP98121176A patent/EP0911390B1/en not_active Expired - Lifetime
- 1992-12-07 ES ES98121177T patent/ES2302343T3/es not_active Expired - Lifetime
- 1992-12-07 US US08/244,603 patent/US6200768B1/en not_active Expired - Lifetime
- 1992-12-07 EP EP08010527A patent/EP2009104A1/en not_active Withdrawn
- 1992-12-07 DE DE69233767T patent/DE69233767D1/de not_active Expired - Lifetime
- 1992-12-07 DK DK93901671T patent/DK0618968T3/da active
- 1992-12-07 AT AT98121175T patent/ATE398176T1/de not_active IP Right Cessation
- 1992-12-07 EP EP93901671A patent/EP0618968B1/en not_active Revoked
- 1992-12-07 AU AU32560/93A patent/AU681071B2/en not_active Ceased
- 1992-12-07 DE DE69233723T patent/DE69233723T2/de not_active Expired - Lifetime
- 1992-12-07 DE DE69230148T patent/DE69230148T2/de not_active Expired - Fee Related
-
1997
- 1997-07-10 AU AU28656/97A patent/AU707736B2/en not_active Ceased
-
1999
- 1999-05-19 JP JP11139268A patent/JP2000026498A/ja active Pending
- 1999-05-19 JP JP11139294A patent/JP2000037188A/ja active Pending
- 1999-05-19 JP JP11139314A patent/JP2000032983A/ja active Pending
-
2008
- 2008-08-04 US US12/185,319 patent/US20090162336A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0618968T3 (da) | Midler til diagnostisering og behandling af Alzheimer's sygdom | |
DE69129302T2 (de) | Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen | |
ATE210296T1 (de) | Immunologisches nachweisverfahren von antikörpern,die gegen gewebe-transglutaminase (ttg) gerichtet sind, verwendung von ttg zur diagnose und therapiekontrolle sowie orales pharmazeutisches mittel enthaltend ttg | |
ES2094733T3 (es) | Deteccion de enfermedades o disfunciones neurologicas. | |
ATE447016T1 (de) | Prüfung und modell für alzheimers-krankheit | |
DE69635740D1 (de) | Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen | |
DK47588D0 (da) | Forloeberprotein for apc-polypeptid, dna koderende for dette samt anvendelse af dna og af proteinet til diagnose | |
DE69432629D1 (de) | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung | |
GB8709803D0 (en) | Treatment of crohn's disease &c | |
DE68928728D1 (de) | Diagnose von retinoblastoma | |
ATE244299T1 (de) | Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis | |
PT998556E (pt) | Diagnostico e tratamento de doencas utilizando anticorpos antivbeta do receptor de celulas t ou peptidos que sao reconhecidos pelos referidos anticorpos e proteina reguladora da secrecao endocrina 1 (esrp1) | |
ATE417930T1 (de) | Proteinkinase npk-110 | |
NO943811L (no) | T-celle-epitoper av hovedallergenene fra Ambriosa artemisiifolia | |
DK0764273T3 (da) | Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose | |
DE69606651T2 (de) | Test zur diagnose von demenz | |
NO950526D0 (no) | T-celleepitoper av raigresspollen-allergen | |
DE69734890D1 (de) | Rdgb-proteine | |
ATE98962T1 (de) | Menschliche rhinoviruspeptide. | |
ES2149155T3 (es) | Peptidos sinteticos que contienen secuencias de factor viia y su utilizacion. | |
NO941458L (da) |